Publications 2016

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P et al. (2016)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Br J Haematol, 175 (3), 410-418
DOI 10.1111/bjh.14241, PubMed 27378674

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH, Nordic Lymphoma Group (2016)
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Biol Blood Marrow Transplant, 23 (3), 428-435
DOI 10.1016/j.bbmt.2016.12.634, PubMed 28039078

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Publications 2015

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

Publications 2014

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H (2014)
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
Leuk Lymphoma, 55 (10), 2319-27
DOI 10.3109/10428194.2013.871632, PubMed 24432894

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N et al. (2014)
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Blood, 123 (19), 2953-9
DOI 10.1182/blood-2013-12-541953, PubMed 24652994

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713

Publications 2012

d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE (2012)
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
J Clin Oncol, 30 (25), 3093-9
DOI 10.1200/JCO.2011.40.2719, PubMed 22851556

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Grp (2012)
Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Br. J. Haematol., 158 (6), 815-816
DOI 10.1111/bjh.12006

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2012)
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
Br J Haematol, 158 (3), 355-62
DOI 10.1111/j.1365-2141.2012.09174.x, PubMed 22640180

Publications 2011

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H (2011)
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study
Br J Haematol, 152 (5), 600-10
DOI 10.1111/j.1365-2141.2010.08519.x, PubMed 21241276

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-1259
DOI 10.1093/annonc/mdr385, PubMed 21926399

Publications 2010

Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, Mahendra P, Holte H (2010)
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocols
Am J Hematol, 85 (4), 261-3
DOI 10.1002/ajh.21648, PubMed 20201088

Publications 2009

Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH (2009)
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma
J Clin Oncol, 27 (26), 4365-70
DOI 10.1200/JCO.2008.21.3116, PubMed 19652064

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2009)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Blood, 115 (8), 1530-3
DOI 10.1182/blood-2009-08-236570, PubMed 20032504

Publications 2008

Bassarova A, Tierens A, Lauritzsen GF, Fosså A, Delabie J (2008)
Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?
Virchows Arch, 453 (4), 407-11
DOI 10.1007/s00428-008-0621-x, PubMed 18696109

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2008)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Blood, 112 (7), 2687-93
DOI 10.1182/blood-2008-03-147025, PubMed 18625886

Publications 2007

Akkök CA, Brinch L, Lauritzsen GF, Solheim BG, Kjeldsen-Kragh J (2007)
Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy
Vox Sang, 93 (1), 42-8
DOI 10.1111/j.1423-0410.2007.00917.x, PubMed 17547564

Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D (2007)
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
Haematologica, 92 (1), 139-40
DOI 10.3324/haematol.10564, PubMed 17229653

Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H (2007)
Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
Leuk Lymphoma, 48 (3), 570-6
DOI 10.1080/10428190601126610, PubMed 17454601

Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S (2007)
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
J Antimicrob Chemother, 59 (4), 711-7
DOI 10.1093/jac/dkm003, PubMed 17327294

Publications 2006

Ikonomou IM, Tierens A, Troen G, Aamot HV, Heim S, Lauritzsen GF, Vålerhaugen H, Delabie J (2006)
Peripheral T-cell lymphoma with involvement of the expanded mantle zone
Virchows Arch, 449 (1), 78-87
DOI 10.1007/s00428-005-0123-z, PubMed 16633785

Publications 2004

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H (2004)
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
Ann Oncol, 15 (7), 1072-8
DOI 10.1093/annonc/mdh262, PubMed 15205201

Trøen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E, Gruszka-Westwood A, Catovsky D, Myklebost O, Lauritzsen G, Hovig E, Delabie J (2004)
Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma
J Mol Diagn, 6 (4), 297-307
DOI 10.1016/S1525-1578(10)60525-9, PubMed 15507668

Publications 1998

Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B (1998)
Clonal deletion of thymocytes as a tumor escape mechanism
Int J Cancer, 78 (2), 216-22
DOI 10.1002/(sici)1097-0215(19981005)78:2<216::aid-ijc16>3.0.co;2-8, PubMed 9754655

Publications 1996

Lauritzsen GF (1996)
Cytotoxicity of idiotype-specific T cells to B lymphoma and plasmacytoma cells in vivo and in vitro
Institute of Immunology and Rheumatology, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 962148032, ISBN 82-90522-20-7

Publications 1995

Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF (1995)
Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies
Eur J Immunol, 25 (11), 3079-86
DOI 10.1002/eji.1830251114, PubMed 7489746

Publications 1994

Lauritzsen GF, Weiss S, Dembic Z, Bogen B (1994)
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors
Proc Natl Acad Sci U S A, 91 (12), 5700-4
DOI 10.1073/pnas.91.12.5700, PubMed 7911244

Publications 1993

Lauritzsen GF, Bogen B (1993)
The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells
Cell Immunol, 148 (1), 177-88
DOI 10.1006/cimm.1993.1100, PubMed 8098665

Lauritzsen GF, Weiss S, Bogen B (1993)
Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo
Scand J Immunol, 37 (1), 77-85
DOI 10.1111/j.1365-3083.1993.tb01668.x, PubMed 8418475

Publications 1991

Lauritzsen GF, Bogen B (1991)
Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type
Scand J Immunol, 33 (6), 647-56
DOI 10.1111/j.1365-3083.1991.tb02537.x, PubMed 1675480

Publications 1990

Bogen B, Lauritzsen GF, Weiss S (1990)
A stimulatory monoclonal antibody detecting T cell receptor diversity among idiotype-specific, major histocompatibility complex-restricted T cell clones
Eur J Immunol, 20 (10), 2359-62
DOI 10.1002/eji.1830201030, PubMed 1700755